Linezolid is a first-in-class oxazolidinone antibiotic for treating serious Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and drug-resistant Streptococcus pneumoniae. It acts by inhibiting bacterial protein synthesis at the initiation stage, binding to the 70S ribosomal complex to block translation, with no cross-resistance to other antibiotic classes. Clinically, it is used for hospital-acquired pneumonia, complicated skin/soft tissue infections, bacteremia, and meningitis caused by resistant strains. It is also used in veterinary medicine for livestock infections. As a synthetic antimicrobial, it serves as a key reference standard in pharmaceutical research and quality control. Its unique mechanism and high potency make it critical for managing multidrug-resistant bacterial infections in humans and animals.

Linezolid is a prescription antibiotic with specific health risks. It may cause myelosuppression (anemia, leukopenia, thrombocytopenia) with prolonged use; monitor blood counts weekly. Common adverse effects include diarrhea, nausea, headache, and dizziness. It is a weak MAO inhibitor; avoid tyramine-rich foods (cheese, wine) and serotonergic drugs (SSRIs) to prevent serotonin syndrome. Hypersensitivity reactions (rash, anaphylaxis) may occur. Wear gloves and goggles when handling; avoid inhalation or ingestion. It is incompatible with strong oxidants and strong bases. Thermal decomposition releases toxic nitrogen oxides and fluorine-containing fumes. Store in a cool, dry, dark area, separated from incompatible substances. Dispose of waste per local pharmaceutical hazardous waste regulations to prevent environmental contamination.